vs
Side-by-side financial comparison of SILVERCORP METALS INC (SVM) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $223.8M, roughly 1.3× SILVERCORP METALS INC). Bio-Techne runs the higher net margin — 12.8% vs -1.3%, a 14.1% gap on every dollar of revenue. Over the past eight quarters, SILVERCORP METALS INC's revenue compounded faster (87.6% CAGR vs 4.2%).
Silvercorp Metals Inc. (Silvercorp) is a Canadian-based, China-focused precious metals company engaged in the acquisition, exploration, and development of silver-containing properties.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
SVM vs TECH — Head-to-Head
Income Statement — Q3 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $223.8M | $295.9M |
| Net Profit | $-2.9M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | -1.3% | 12.8% |
| Revenue YoY | — | -6.4% |
| Net Profit YoY | — | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $223.8M | $295.9M | ||
| Q2 25 | $72.2M | $317.0M | ||
| Q1 25 | — | $316.2M | ||
| Q4 24 | $172.5M | $297.0M | ||
| Q3 24 | $114.0M | $289.5M | ||
| Q2 24 | $60.0M | $306.1M | ||
| Q1 24 | — | $303.4M | ||
| Q4 23 | $174.0M | $272.6M |
| Q4 25 | $-2.9M | $38.0M | ||
| Q2 25 | $28.1M | $-17.7M | ||
| Q1 25 | — | $22.6M | ||
| Q4 24 | $42.1M | $34.9M | ||
| Q3 24 | $28.0M | $33.6M | ||
| Q2 24 | $13.2M | $40.6M | ||
| Q1 24 | — | $49.1M | ||
| Q4 23 | $18.8M | $27.5M |
| Q4 25 | — | 64.6% | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% | ||
| Q4 23 | — | 64.8% |
| Q4 25 | — | 18.4% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | 30.5% | 16.0% | ||
| Q3 24 | 30.7% | 13.8% | ||
| Q2 24 | 30.0% | 15.0% | ||
| Q1 24 | — | 22.1% | ||
| Q4 23 | 16.8% | 13.9% |
| Q4 25 | -1.3% | 12.8% | ||
| Q2 25 | 39.0% | -5.6% | ||
| Q1 25 | — | 7.1% | ||
| Q4 24 | 24.4% | 11.7% | ||
| Q3 24 | 24.5% | 11.6% | ||
| Q2 24 | 22.0% | 13.3% | ||
| Q1 24 | — | 16.2% | ||
| Q4 23 | 10.8% | 10.1% |
| Q4 25 | — | $0.24 | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 | ||
| Q4 23 | $0.11 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | — | $2.0B |
| Total Assets | — | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.9M | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M | ||
| Q1 24 | — | $145.3M | ||
| Q4 23 | — | $135.7M |
| Q4 25 | — | $260.0M | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M | ||
| Q4 23 | — | $447.0M |
| Q4 25 | — | $2.0B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $2.0B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.1B | ||
| Q2 24 | — | $2.1B | ||
| Q1 24 | — | $2.0B | ||
| Q4 23 | — | $2.0B |
| Q4 25 | — | $2.5B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | — | $2.7B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B | ||
| Q4 23 | — | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× | ||
| Q4 23 | — | 0.23× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $107.9M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $107.9M | — | ||
| Q2 25 | $40.0M | $98.2M | ||
| Q1 25 | — | $41.1M | ||
| Q4 24 | $81.3M | $84.3M | ||
| Q3 24 | $57.7M | $63.9M | ||
| Q2 24 | $28.9M | $75.5M | ||
| Q1 24 | — | $81.0M | ||
| Q4 23 | $79.9M | $83.1M |
| Q4 25 | — | — | ||
| Q2 25 | — | $93.3M | ||
| Q1 25 | — | $31.0M | ||
| Q4 24 | — | $77.5M | ||
| Q3 24 | $33.8M | $54.7M | ||
| Q2 24 | $17.0M | $57.5M | ||
| Q1 24 | — | $64.5M | ||
| Q4 23 | $45.7M | $68.3M |
| Q4 25 | — | — | ||
| Q2 25 | — | 29.4% | ||
| Q1 25 | — | 9.8% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | 29.6% | 18.9% | ||
| Q2 24 | 28.3% | 18.8% | ||
| Q1 24 | — | 21.3% | ||
| Q4 23 | 26.2% | 25.0% |
| Q4 25 | — | — | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 21.0% | 3.2% | ||
| Q2 24 | 19.8% | 5.9% | ||
| Q1 24 | — | 5.4% | ||
| Q4 23 | 19.7% | 5.5% |
| Q4 25 | — | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 1.93× | 2.42× | ||
| Q3 24 | 2.06× | 1.90× | ||
| Q2 24 | 2.19× | 1.86× | ||
| Q1 24 | — | 1.65× | ||
| Q4 23 | 4.25× | 3.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SVM
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
